{"id":"u101","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of genital yeast infections"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, U101 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.","oneSentence":"U101 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:54:39.034Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT07184827","phase":"PHASE3","title":"Evaluate the Efficacy and Safety of U101 Oral Capsules in the Prevention of Uncomplicated rUTIs in Women","status":"RECRUITING","sponsor":"TCM Biotech International Corp.","startDate":"2020-10-14","conditions":"Recurrent Urinary Tract Infections in Women","enrollment":348},{"nctId":"NCT05245591","phase":"PHASE2, PHASE3","title":"Radiation Cystitis Treated With Pentosan Polysulfate Sodium Trial","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2022-04-29","conditions":"Radiation Cystitis","enrollment":72},{"nctId":"NCT00256542","phase":"PHASE2","title":"Study of U101 for Bladder Pain and/or Urgency","status":"COMPLETED","sponsor":"Urigen","startDate":"2006-01","conditions":"Pelvic Pain, Interstitial Cystitis, Bladder Diseases","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["pentosan polysulfate sodium (PPS)"],"phase":"phase_3","status":"active","brandName":"U101","genericName":"U101","companyName":"TCM Biotech International Corp.","companyId":"tcm-biotech-international-corp","modality":"Small molecule","firstApprovalDate":"","aiSummary":"U101 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}